Morphine Sulfate Immediate Release
GPTKB entity
Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:morphine_sulfate
|
| gptkbp:ATCCode |
N02AA01
|
| gptkbp:brand |
gptkb:Roxanol
gptkb:MSIR |
| gptkbp:contraindication |
respiratory depression
acute asthma paralytic ileus |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:eliminationHalfLife |
2-4 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
immediate release
|
| https://www.w3.org/2000/01/rdf-schema#label |
Morphine Sulfate Immediate Release
|
| gptkbp:indication |
pain management
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
mu-opioid receptor agonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:riskFactor |
addiction
tolerance overdose dependence |
| gptkbp:routeOfAdministration |
oral
intramuscular subcutaneous intravenous |
| gptkbp:sideEffect |
nausea
constipation drowsiness respiratory depression |
| gptkbp:bfsParent |
gptkb:MSIR
|
| gptkbp:bfsLayer |
7
|